Highest-materiality recent filing
CNBX Pharmaceuticals issues $45K promissory note to 3i L.P. for working capital
Non-convertible note principal $45,000, due July 1, 2026, with 5% simple interest.
CNBX Pharmaceuticals enters convertible note with $55K initial, up to $850K, 35% discount conversion
Issue Date Jan 23, 2025; maturity Oct 30, 2025; 10% interest, 9% OID, default interest 22%.
CNBX Pharmaceuticals replaces independent auditor with no disagreements
Replaced Weinstein International CPA with Elkana Amitai, CPA effective March 18, 2024.
Two directors of CNBX Pharmaceuticals resign effective Jan 31, 2023
Dr. Inbar Maymon Pomeranchik resigned as director; no disagreement with management.
Director Shaul Yemal resigns from CNBX Pharmaceuticals board effective Dec 25, 2022
Shaul Yemal resigned as Director and Board Member on December 25, 2022.
CNBX appoints Dr. Sanja Goldberg as CTO, replacing Dr. Eyal Ballan
Dr. Eyal Ballan resigned as CTO and employment ended effective July 20, 2022.
CNBX Pharma effects 1:120 reverse split and cuts authorized preferred to 5M shares
Reverse stock split of 1:120 effective May 12, 2022; par value unchanged.
Cannabics Pharmaceuticals changes name to CNBX Pharmaceuticals, ticker unchanged
Name change effective March 28, 2022; stock continues trading on OTCQB under symbol CNBX.
Cannabics defaults on $1.375M note, obtains forbearance; issues $280K demand note
Forbearance with institutional investor on $1.375M Senior Secured Note due Dec 21, 2021; forbearance through May 7, 2022.
Company defaulted on $1,375,000 Senior Secured Convertible Promissory Note due December 21, 2021.
Cannabics appoints Shaul Yemal to Board as independent director and Audit Committee member
Board expanded to five members; Shaul Yemal appointed as independent director and Audit Committee member.
Cannabics Pharmaceuticals appoints Gabriel Yariv as Executive Chairman
Gabriel Yariv appointed as Executive Chairman effective September 3, 2021.
Cannabics Pharmaceuticals appoints Dr. Gil Feiler as Independent Board Member
Dr. Gil Feiler appointed as Independent Board Member effective July 15, 2021.
Dr. Inbar Maymon Pomeranchik appointed as independent board member of Cannabics Pharmaceuticals
Dr. Inbar Maymon-Pomeranchik, 43, appointed to board effective July 1, 2021.
On January 31 st , 2023, Dr. Inbar Maymon Pomeranchik resigned from her position as a Director and Board Member.
Also on January 31 st , 2023, Gil Feiler also presented his resignation as a Director and Board Member.
On December 25th, 2022, Shaul Yemal resigned his position as Director and Board Member.
Dr. Sanja Goldberg was appointed as the Company’s new Chief Technology Officer on July 24 th , 2022.
Chief Technology Officer Dr. Eyal Ballan has resigned his position as CTO and his employment with the Company has ended effective July 20 th , 2022.
On November 16 th , 2021, the Board of Directors (the “Board”) increased the size of the Board to five (5) members, and appointed Mr. Shaul Yemal to the Board as an Independent Director and as a member of the Audit Committee.
On September 5 rd , 2021, the Board of Directors nominated fellow Director Mr. Gabriel Yariv as Executive Chairman of the Board.
On July 15th, 2021, the Board of Directors appointed Dr. Gil Feiler as an Independent Board Member
On July 1 st , 2021, the Board of Directors appointed Dr. Inbar Maymon Pomeranchik as an Independent Board Member.
Max materiality 0.70 · Median 0.50 · Most common event leadership